crashbandicoottrilogynintendoswitch| Jiuzhou Pharmaceutical (603456.SH): In July 2023, the company was elected as the deputy director of the Zhejiang Province Synthetic Biology Industry Technology Alliance

Gelonghui May 8 丨 Jiuzhou Pharmaceutical (603456)(603456crashbandicoottrilogynintendoswitch.SH) said on the investor interaction platformcrashbandicoottrilogynintendoswitchWith years of new drug research and development and technology accumulation, the company has many R & D technology platforms such as catalysis, peptides, and coupling. In July 2023, the company was elected as the deputy director of the Zhejiang Province Synthetic Biology Industry Technology Alliance. The company's R & D team focuses on developing high-performance enzymes and high-efficiency enzyme catalytic processes, and has made good progress in the bio-green manufacturing of small molecule drugs. For example, in the development of statin drug processes, significantly reducing costs and improving product market competitiveness. At the same time, the company is actively deploying new molecular biosynthesis fields such as peptide drugs.